Kimberly Cook
Family · Tustin, CANPI 1831423896
Payments from drug & device makers
Across 260 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$667
- AstraZeneca$436
- AbbVie$337
- Insulet Corporation$295
- Bayer$234
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,122100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 77 | $1,156 |
| Novo Nordisk | 30 | $667 |
| AstraZeneca(2 entities) | 20 | $436 |
| AbbVie | 16 | $337 |
| Insulet Corporation | 14 | $295 |
| Bayer | 6 | $234 |
| Amgen | 9 | $190 |
| Sanofi-aventis U.S. LLC | 11 | $188 |
| Antares Pharma, Inc. | 8 | $171 |
| Corcept Therapeutics | 6 | $159 |
| Xeris Pharmaceuticals, Inc. | 8 | $148 |
| Dexcom, Inc. | 7 | $146 |
| Mannkind Corporation | 9 | $143 |
| Recordati_rare_diseases_inc. | 4 | $106 |
| Medtronic | 5 | $106 |
| Radius Health, Inc. | 3 | $72 |
| Abbott | 3 | $68 |
| Ascendis Pharma Endocrinology Inc | 2 | $51 |
| Boehringer Ingelheim | 2 | $50 |
| Ultragenyx Pharmaceutical Inc. | 3 | $49 |
| Merck | 3 | $48 |
| Novartis | 2 | $45 |
| IBSA Pharma Inc. | 2 | $37 |
| BD | 1 | $36 |
| Averitas Pharma Inc. | 1 | $26 |
| GSK | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,133 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $147,135 |
| MounjaroTirzepatide | 70 | $113,199 |
| JardianceEmpagliflozin | 41 | $59,482 |
| TrulicityDulaglutide | 35 | $50,027 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $47,479 |
| FarxigaDapagliflozin Propanediol | 37 | $31,084 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $28,464 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $22,046 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $19,814 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $17,441 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 12 | $16,939 |
| TradjentaLinagliptin | 18 | $16,682 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $13,816 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $12,420 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 15 | $8,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,156 | $170,118135 claims |
| Novo NordiskOzempic | $667 | $147,135101 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $50 | $95,97777 claims |
| AstraZenecaFarxiga | $436 | $31,08437 claims |
| AbbVieSynthroid | $337 | $2,14522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Tustin
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.